Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen

Nature Medicine

Volumn 22, Issue 10, 2016, Pages 1101-1107

  Xu, Miao ^a,b   Lee, Emily M ^c   Wen, Zhexing ^d,e   Cheng, Yichen ^c   Huang, Wei Kai ^e   Qian, Xuyu ^e   Tcw, Julia ^f   Kouznetsova, Jennifer ^a   Ogden, Sarah C ^c   Hammack, Christy ^c   Jacob, Fadi ^e   Nguyen, Ha Nam ^e   Itkin, Misha ^a   Hanna, Catherine ^c   Shinn, Paul ^a   Allen, Chase ^c   Michael, Samuel G ^a   Simeonov, Anton ^a   Huang, Wenwei ^a   Christian, Kimberly M ^e   Goate, Alison ^f   Brennand, Kristen J ^f   Huang, Ruili ^a   Xia, Menghang ^a   Ming, Guo Li ^e   Zheng, Wei ^a   Song, Hongjun ^e   Tang, Hengli ^c   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c FLORIDA STATE UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; EMRICASAN; NICLOSAMIDE; 3-(2-(2-TERT-BUTYLPHENYLAMINOOXALYL)AMINOPROPIONYLAMINO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID; CASPASE INHIBITOR; VALERIC ACID DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; ASTROCYTE; BRAIN CORTEX; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG REPOSITIONING; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MONOLAYER CULTURE; NERVE CELL NECROSIS; NEURAL STEM CELL; NEUROPROTECTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; ZIKA FEVER; BRAIN; CELL DEATH; CELL LINE; CYTOPLASM; DRUG EFFECTS; INDUCED PLURIPOTENT STEM CELL; MICROCEPHALY; NERVE CELL; ZIKA VIRUS; ZIKA VIRUS INFECTION;

ASTROCYTES; BRAIN; CASPASE 3; CASPASE INHIBITORS; CELL DEATH; CELL LINE; DRUG REPOSITIONING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICROCEPHALY; NEURAL STEM CELLS; NEURONS; NICLOSAMIDE; ORGANOIDS; PENTANOIC ACIDS; VIRUS REPLICATION; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 84984662505     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4184     Document Type: Article

References (65)

1. Dick, G. W., Kitchen, S. F. & Haddow, A. J. Zika virus. I. Isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 46, 509-520 (1952).
2. Heymann, D. L. et al. Zika virus and microcephaly: why is this situation a PHEIC Lancet 387, 719-721 (2016).
3. D'Ortenzio, E. et al. Evidence of sexual transmission of Zika virus. N. Engl. J. Med. 374, 2195-2198 (2016).
4. Foy, B. D. et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg. Infect. Dis. 17, 880-882 (2011).
5. McCarthy, M. Zika virus was transmitted by sexual contact in Texas, health officials report. Br. Med. J. 352, i720 (2016).
6. Musso, D. et al. Potential sexual transmission of Zika virus. Emerg. Infect. Dis. 21, 359-361 (2015).
7. Brasil, P. et al. Zika virus infection in pregnant women in Rio de Janeiro-preliminary report. N. Engl. J. Med. (2016). http://dx. doi. org/10. 1056/NEJMoa1602412
8. Petersen, E. et al. Rapid spread of Zika virus in the Americas-implications for public health preparedness for mass gatherings at the 2016 Brazil Olympic games. Int. J. Infect. Dis. 44, 11-15 (2016).
9. Driggers, R. W. et al. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N. Engl. J. Med. 374, 2142-2151 (2016).
10. Mlakar, J. et al. Zika virus associated with microcephaly. N. Engl. J. Med. 374, 951-958 (2016).
11. Rasmussen, S. A., Jamieson, D. J., Honein, M. A. & Petersen, L. R. Zika virus and birth defects-reviewing the evidence for causality. N. Engl. J. Med. 374, 1981-1987 (2016).
12. Cao-Lormeau, V. M. et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study. Lancet 387, 1531-1539 (2016).
13. Araujo, L. M., Ferreira, M. L. & Nascimento, O. J. Guillain-Barré syndrome associated with the Zika virus outbreak in Brazil. Arq. Neuropsiquiatr. 74, 253-255 (2016).
14. Fontes, C. A., Dos Santos, A. A. & Marchiori, E. Magnetic resonance imaging findings in Guillain-Barré syndrome caused by Zika virus infection. Neuroradiology http://dx. doi. org/10. 1007/s00234-016-1687-9 (2016).
15. Tang, H. et al. Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell 18, 587-590 (2016).
16. Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science 352, 816-818 (2016).
17. Qian, X. et al. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. Cell 165, 1238-1254 (2016).
18. Rossi, S. L. et al. Characterization of a novel murine model to study Zika virus. Am. J. Trop. Med. Hyg. 94, 1362-1369 (2016).
19. Lazear, H. M. et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe 19, 720-730 (2016).
20. Cugola, F. R. et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534, 267-271 (2016).
21. Li, C. et al. Zika virus disrupts neural progenitor development and leads to microcephaly in mice. Cell Stem Cell 19, 120-126 (2016).
22. Miner, J. J. et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell 165, 1081-1091 (2016).
23. Wu, K. Y. et al. Vertical transmission of Zika virus targeting the radial glial cells affects cortex development of offspring mice. Cell Res. 26, 645-654 (2016).
24. Dang, J. et al. Zika virus depletes neural progenitors in human cerebral organoids through activation of the innate immune receptor TLR3. Cell Stem Cell 19, 258-265 (2016).
25. Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature http:// dx. doi. org/10. 1038/nature18952 (2016).
26. Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science http://dx. doi. org/10. 1126/science. Aah6157 (2016).
27. Yang, Y. M. et al. A small-molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 12, 713-726 (2013).
28. Sun, W., Sanderson, P. E. & Zheng, W. Drug combination therapy increases successful drug repositioning. Drug Discov. Today 21, 1189-1195 (2016).
29. Kouznetsova, J. et al. Identification of 53 compounds that block Ebola-virus-like particle entry via a repurposing screen of approved drugs. Emerg. Microbes Infect. 3, e84 (2014).
30. Johansen, L. M. et al. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci. Transl. Med. 7, 290ra89 (2015).
31. Chen, C. Z. et al. High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements. Antimicrob. Agents Chemother. 55, 667-675 (2011).
32. Debnath, A. et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat. Med. 18, 956-960 (2012).
33. Sun, W. et al. Chemical signatures and new drug targets for gametocytocidal drug development. Sci. Rep. 4, 3743 (2014).
34. Sun, W. et al. Rapid identification of antifungal compounds against Exserohilum rostratum using high-throughput drug repurposing screens. PLoS One 8, e70506 (2013).
35. He, S. et al. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci. Transl. Med. 7, 282ra49 (2015).
36. Barrows, N. J. et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe 20, 259-270 (2016).
37. Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J. Biomol. Screen. 4, 67-73 (1999).
38. Hamel, R. et al. Biology of Zika virus infection in human skin cells. J. Virol. 89, 8880-8896 (2015).
39. Nowakowski, T. J. et al. Expression analysis highlights AXL as a candidate Zika virus entry receptor in neural stem cells. Cell Stem Cell 18, 591-596 (2016).
40. Schang, L. M., St Vincent, M. R. & Lacasse, J. J. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir. Chem. Chemother. 17, 293-320 (2006).
41. Badia, R. et al. Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. J. Antimicrob. Chemother. 71, 387-394 (2016).
42. Németh, G. et al. Novel, selective CDK9 inhibitors for the treatment of HIV infection. Curr. Med. Chem. 18, 342-358 (2011).
43. Okamoto, M. et al. Selective inhibition of HIV-1 replication by the CDK9 inhibitor FIT-039. Antiviral Res. 123, 1-4 (2015).
44. Van Duyne, R. et al. Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription. J. Mol. Biol. 425, 812-829 (2013).
45. Yamamoto, M. et al. CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses. J. Clin. Invest. 124, 3479-3488 (2014).
46. Zhang, J., Li, G. & Ye, X. Cyclin T1-CDK9 interacts with influenza A virus polymerase and facilitates its association with cellular RNA polymerase II. J. Virol. 84, 12619-12627 (2010).
47. Bell, T. M., Field, E. J. & Narang, H. K. Zika virus infection of the central nervous system of mice. Arch. Gesamte Virusforsch. 35, 183-193 (1971).
48. Haddad, J. J. Current opinion on 3-[2-[(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2, 3, 5, 6-tetrafluoro-phenoxy)-pentanoic acid, an investigational drug targeting caspases and caspase-like proteases: The clinical trials in sight and recent anti-inflammatory advances. Recent Pat. Inflamm. Allergy Drug Discov. 7, 229-258 (2013).
49. Hoglen, N. C. et al. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2, 3, 5, 6-tetrafluoro-phenoxy)-pentanoic acid): A liver-targeted caspase inhibitor. J. Pharmacol. Exp. Ther. 309, 634-640 (2004).
50. Barreyro, F. J. et al. The pan-caspase inhibitor emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 35, 953-966 (2015).
51. Shiffman, M. L. et al. Clinical trial: The efficacy and safety of oral PF-03491390, a pan-caspase inhibitor-a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 31, 969-978 (2010).
52. Pfizer, Inc. Ibrance (palbociclib) capsules (prescribing information). (Pfizer, Inc., New York, 2015).
53. Mansuy, J. M. et al. Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen Lancet Infect. Dis. 16, 405 (2016).
54. Andrews, P., Thyssen, J. & Lorke, D. The biology and toxicology of molluscicides, Bayluscide. Pharmacol. Ther. 19, 245-295 (1982).
55. Al-Hadiya, B. M. H. Niclosamide: comprehensive profile. Profiles Drug Subst. Excip. Relat. Methodol. 32, 67-96 (2005).
56. Wu, C. J. et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob. Agents Chemother. 48, 2693-2696 (2004).
57. Jurgeit, A. et al. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog. 8, e1002976 (2012).
58. Fang, J. et al. Identification of three antiviral inhibitors against Japanese encephalitis virus from library of pharmacologically active compounds 1, 280. PLoS One 8, e78425 (2013).
59. Khanim, F. L. et al. Re-deployment-based drug screening identifies the antihelminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. Blood Cancer J. 1, e39 (2011).
60. Wen, Z. et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature 515, 414-418 (2014).
61. Brennand, K. J. et al. Modeling schizophrenia using human induced pluripotent stem cells. Nature 473, 221-225 (2011).
62. Topol, A. et al. Increased abundance of translation machinery in stem-cell-derived neural progenitor cells from four schizophrenia patients. Transl. Psychiatry 5, e662 (2015).
63. Huang, R. et al. The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med. 3, 80ps16 (2011).
64. Inglese, J. et al. Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. USA 103, 11473-11478 (2006).
65. Wang, Y., Jadhav, A., Southal, N., Huang, R. & Nguyen, D. T. A grid algorithm for high-throughput fitting of dose-response curve data. Curr. Chem. Genomics 4, 57-66 (2010).